Form 4: Sarepta Therapeutics EVP Cristin Rothfuss Reports Stock Disposals to Cover Tax Obligations
SEC Form 4 Filing
EVP and General Counsel of Sarepta Therapeutics, Cristin Rothfuss, reports disposing of shares to cover tax withholding obligations related to vesting of restricted stock units.
Summary
- Cristin Rothfuss, EVP and General Counsel of Sarepta Therapeutics, reported changes in beneficial ownership of company stock on March 4, 2025.
- The transactions involved the disposal of common stock to satisfy tax withholding obligations related to the vesting of restricted stock units.
- A total of 584 shares were disposed of at a price of $101.34 per share.
- Following the reported transactions, Rothfuss directly owns 13,325 shares of Sarepta Therapeutics common stock.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing related to stock transactions by an executive. It doesn't inherently convey positive or negative sentiment.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. Disposals to cover tax obligations are common when restricted stock units vest.
Key Dates
| Date | Description |
|---|---|
| 03/03/2021 | Date of grant for the restricted stock units related to the tax withholding. |
| 03/04/2025 | Date of the stock disposal transaction. |
| 03/06/2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.